Please assess the completion status of the following clinical trial:

Trial Title: GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Subject is male and is greater than or equal to 18 years old.~* Subject must be scheduled to undergo standard of care prostatectomy for presumed localized prostate cancer at the NIH Clinical Center.~* Recent (within 12 months of study entry but not within 8-12 weeks before start of imaging study) prostate biopsy indicating the presence of adenocarcinoma of the prostate gland in which at least sextant biopsies were obtained.~* Subjects must have a minimum of 1 positive-for-cancer biopsy core.~* Serum creatinine within 2 weeks prior to MR imaging less than or equal to 1.8 mg/dl and eGFR must be greater than 30 ml/min/1.73m(2)~* Chemistry parameters: AST and ALT 2 x of the upper limits of normal; total bilirubin, of less than or equal to 2 x the upper limits of normal or less than 3.0 mg/dl in patients with Gilbert's syndrome.~* Eastern Cooperative Oncology Group (ECOG) Performance score of 0 to 2.~* Ability to provide informed consent. All subjects must sign an informed consent form indicating their understanding of the investigational nature and risks of the study before any protocol-related studies are performed.~* The subject has a clinically acceptable medical history, physical examination and vital signs findings during the screening period (from within 21 days before administration of GE-148 (18F) Injection).~EXCLUSION CRITERIA:~* Known allergy to gadolinium.~* Subjects for whom participating would significantly delay the scheduled standard of care therapy.~* Subjects with any coexisting medical or psychiatric condition that is likely to interfere with study procedures and/or results.~* Subjects with severe claustrophobia unresponsive to oral anxiolytics.~* Subjects with contraindications to MRI~  * Subjects weighing more than 136 kg (weight limit for scanner table).~ * Subjects with pacemakers, cerebral aneurysm clips, shrapnel injury, or other implanted electronic devices or metal not compatible with MRI.~* Subjects with contraindication to endorectal coil placement~  * Severe hemorrhoids.~ * Surgically absent rectum.~* Other medical conditions deemed by the principle investigator (or associates) or sponsor to make the subject ineligible for protocol procedures.~* Subjects who have previously received radiation therapy to the pelvis.~* Subjects who have received androgen-deprivation therapy.~* The subject has received, or is scheduled to receive, another IMP from 1 month before to 1 week after administration of GE-148 (18F) Injection.~* Subjects with chronic renal failure (eGFR less than 30 ml/min/1.73m(2)).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GE 148-002 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues